Comparative Pharmacology
Head-to-head clinical analysis: IMODIUM A D versus LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMODIUM A D versus LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE.
IMODIUM A-D vs LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide is a synthetic piperidine derivative that acts as an agonist at mu-opioid receptors in the myenteric plexus of the gastrointestinal tract. It inhibits peristalsis by decreasing circular and longitudinal smooth muscle activity, prolonging gastrointestinal transit time, and increasing water and electrolyte absorption. It also increases anal sphincter tone, reducing fecal urgency and incontinence. Loperamide has poor bioavailability and does not cross the blood-brain barrier significantly at therapeutic doses, limiting central opioid effects.
Loperamide binds to mu-opioid receptors in the intestinal wall, reducing peristalsis and increasing intestinal transit time, allowing for greater absorption of water and electrolytes. It also decreases fecal volume and increases stool consistency. Simethicone reduces the surface tension of gas bubbles in the stomach and intestines, facilitating their coalescence and passage via belching or flatulence.
4 mg orally initially, then 2 mg after each unformed stool; maximum 8 mg/day for OTC use; 16 mg/day for prescription use. Duration not to exceed 2 days.
2 tablets (4 mg loperamide hydrochloride / 250 mg simethicone) orally after first loose stool, then 1 tablet (2 mg/125 mg) after each subsequent loose stool; maximum 4 tablets (8 mg/500 mg) per day for no more than 2 days.
None Documented
None Documented
Terminal elimination half-life is approximately 9-14 hours (mean 11.2 hours) in patients with diarrhea; clinical significance: steady-state achieved within 2-4 days.
Loperamide: 7-14 hours (mean 10.8 hours) in healthy adults; prolonged to 18-26 hours in hepatic impairment.
Primarily fecal (approximately 95% as unchanged drug and metabolites) with minimal renal excretion (<1% unchanged).
Loperamide: 97% fecal, 3% renal. Simethicone: excreted unchanged in feces.
Category C
Category A/B
Antidiarrheal
Antidiarrheal